Ekkehard Beck

Moderna Therapeutics (United States)

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Nicolas Van de Velde

Moderna Therapeutics (United States)

Michele Kohli

Health Economics and Outcomes Research (United Kingdom)

Michael Maschio

Health Economics and Outcomes Research (United Kingdom)

Keya Joshi

Moderna Therapeutics (United States)

Maarten J. Postma

University Medical Center Groningen

Mary T. Bausch-Jurken

Moderna Therapeutics (United States)

Emmanuel Aris

GlaxoSmithKline (Belgium)

Huib A.M. Kerstjens

University Medical Center Groningen

James A. Mansi

Moderna Therapeutics (United States)

Jane Whelan

GGD Rotterdam-Rijnmond

Cooperative Institutions

Royal Brompton Hospital

Inserm

AstraZeneca (United Kingdom)

AstraZeneca (United States)

Moderna Therapeutics (United States)

Observational & Pragmatic Research Institute

GlaxoSmithKline (Belgium)

Harvard University

Boehringer Ingelheim (Germany)

AstraZeneca (Brazil)

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Cost-effectiveness Analysis of COVID-19 mRNA XBB.1.5 Fall 2023 Vaccination in the Netherlands

Advances in Therapy (2025)

Florian Zeevat Simon van der Pol Tjalke A. Westra Ekkehard Beck Maarten J. Postma

2019-20 coronavirus outbreak

Coronavirus Infections

10.1007/s12325-025-03112-y

Cite

Citations (0)

Healthcare Resource Utilization (HCRU) and Direct Medical Costs Associated with Long COVID or Post-COVID-19 Conditions: Findings from a Literature Review

Journal of Market Access & Health Policy (2025)

Elżbieta Łukomska K. Kloc Malwina Kowalska Aleksandra Matjaszek Keya Joshi

Approximately 10-20% of individuals suffering from COVID-19 develop prolonged symptoms known as long COVID or post-COVID condition (LC). This review aimed to assess healthcare resource use (HCRU) and healthcare costs associated with LC. Because LC is not clearly defined and often remains undiagnosed, studies reporting on long-term follow-up of individuals with a COVID-19 diagnosis were also included. Among the 41 publications included, 36 reported on HCRU and 16 on costs. Individuals with LC had significantly elevated HCRU and healthcare costs vs. controls without a COVID-19 diagnosis over ≥15 months, with a 7.6-13.1% increase in total healthcare costs per person per month as assessed by difference-in-difference analysis. Among studies that did not specifically refer to LC, having a COVID-19 diagnosis was associated with a significant 4-10% increase in long-term total HCRU over 6-8 months and a 1.3- to 2.9-fold relative increase in total healthcare costs over 6 months. Due to the heterogeneity of the included studies, high-quality evidence is needed to better understand the economic burden of LC. In the absence of effective treatments, prioritizing the prevention of acute COVID-19, e.g., through vaccination, may be crucial for preventing LC and the associated long-term HCRU and medical spending.

2019-20 coronavirus outbreak

10.3390/jmahp13010007

Cite

Citations (0)

PIN118 Impact of Invasive Meningococcal Disease on Life Expectancy and Socioeconomic Burden in France: A Real World SNIIRAM Database Analysis

Value in Health (2020)

Jing Shen S. Bouée M. Neine Emmanuel Aris Corinne Emery

Case fatality rate

10.1016/j.jval.2020.08.959

Cite

Citations (0)

Le fardeau économique des infections invasives à méningocoque en France : une étude rétrospective cas témoins sur base de données

Revue d Épidémiologie et de Santé Publique (2021)

C. Weil-Olivier Muhamed‐Kheir Taha Corinne Emery G. Nachbaur Ekkehard Beck

10.1016/j.respe.2021.05.016

Cite

Citations (0)

TIOTROPIUM REDUCES ASTHMA EXACERBATIONS IN PATIENTS WITH UNCONTROLLED ASTHMA AND PERSISTENT AIRFLOW OBSTRUCTION DESPITE TREATMENT IN ACCORDANCE WITH GUIDELINES

Huib A.M. Kerstjens Ronald Dahl Ekkehard Beck Mark Vandewalker Michael E. Engel

Asthma Exacerbations

Bronchodilator Agents

Cite

Citations (1)

A Qualitative Concept Elicitation Study to Understand Patient-Reported Symptoms and Impacts of Neisseria gonorrhoeae Infections in the United States

Sexually Transmitted Diseases (2024)

Zeki Kocaata Brooke M. Currie Ekkehard Beck Erica Zaiser Katelyn Cutts

Background Gonorrhea is the second most common bacterial sexually transmitted infection in the United States, with rising rates. Emerging antimicrobial resistance threatens public health, and vaccines are in development. This study documents patient-reported gonorrhea symptoms and health-related quality-of-life (HRQoL) impact in women who have sex with men (WSM), men who have sex with women (MSW), and men who have sex with men (MSM). Methods Semistructured qualitative interviews were conducted (April 2021–March 2022) among US adults with recent (≤6 months) confirmed gonorrhea. Concept saturation was achieved, confirming adequate participant numbers to meet objectives. Elicited symptom and HRQoL impacts were used to develop a conceptual disease model. Common patient-reported outcome measure (PROM) items were compared with elicited concepts. Results Thirty-two participants (15 WSM, 8 MSW, and 9 MSM) were included. Eight were asymptomatic, 6 had repeat infections, and 5 women and 4 men had complications (i.e., infertility or pelvic inflammatory disease, and urethritis, respectively). The most frequently reported symptoms were vaginal discharge (n = 11 of 12), dysuria (n = 10 of 12), and abdominal/vaginal pain (n = 9 of 12) for symptomatic WSM; dysuria (n = 5 of 6) and penile discharge (n = 4 of 6) for symptomatic MSW; and throat, testicular, or rectal pain (n = 4 of 6) for symptomatic MSM. All (symptomatic and asymptomatic) participants reported HRQoL impacts including negative emotional experiences (n = 31 of 32), and interference with sexual activity (n = 30 of 32), relationships (n = 24 of 32), and social life (n = 17 of 32). Concepts were poorly represented in existing PROMs. Conclusions Participants reported a diverse range of symptoms and HRQoL impacts, to help inform the value of new treatment and prevention options. More research is needed to quantify patient burden and develop PROMs.

Dysuria

10.1097/olq.0000000000001958

Cite

Citations (0)

The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA fall 2023 vaccines in the United States

Journal of Medical Economics (2023)

Michele Kohli Michael Maschio Keya Joshi Amy S. Lee Kelly Fust

Aims To assess the potential clinical impact and cost-effectiveness of COVID-19 mRNA vaccines updated for fall 2023 in adults ≥18 years over a 1-year analytic time horizon (September 2023-August 2024).

2019-20 coronavirus outbreak

10.1080/13696998.2023.2281083

Cite

Citations (17)

HEALTH BEHAVIORS AND HEALTH OUTCOMES: COMPARISON AMONG THREE OLDER AGE COHORTS

Innovation in Aging (2017)

Yan Su Hardeep K. Obhi Ekkehard Beck Jennifer A. Margrett

Previous research found differences in social involvement, aging perception and health status among different older age cohorts (Field & Minkler, 1988; Garfein & Herzog, 1995; Seccombe & Ishii-Kuntz, 1991). In the current study, we aim to examine differences in both health-related behaviors and health outcomes among the three age groups: young old (65–74), the old (75–84), and the oldest old (85 +). To investigate this, we collected data from older adults residing in one Midwest county (N=433), among which 76% were female and 28.2% were young-old (n= 122), 42.3% were old (n = 183) and 29.6% were the oldest old (n = 128). A series of analysis of variance tests and chi-square tests were conducted. The results showed no significant difference in self-reported chronic diseases [x2 (2, N = 433) = 4.25, p = .12], self-reported depression [x2 (2, N = 433) = 1.63, p = .44], exercise duration every time they exercise [F (2,430) = 1, p =.37], nor in exercise frequency [F (2,430) = 2.79, p =.06]. However, the old had significantly higher social participation frequency than young old [x2 (1, N = 305) = 6.51, p = .01] and the oldest old [x2 (1, N = 311) = 4.86, p = .03]. Our results showed no significant differences in health outcomes but differences in health behaviors (social participation) were apparent. Thus, our study implied the compensatory effect of social participation in health and the fact that more attention may need to be paid to young-old.

Depression

Age groups

10.1093/geroni/igx004.1888

Cite

Citations (0)

Real-World Effectiveness of a Third Dose of mRNA-1273 versus BNT162b2 on Inpatient and Medically Attended COVID-19 among Immunocompromised Adults in the United States

medRxiv (Cold Spring Harbor Laboratory) (2024)

Tianyu Sun Linwei Li Katherine E. Mues Mihaela Georgieva Brenna Kirk

ABSTRACT Recent data have shown elevated infection rates in several subpopulations at risk of SARS-CoV-2 infection and COVID-19, including immunocompromised (IC) individuals. Previous research suggests that IC persons have reduced risks of hospitalization and medically-attended COVID-19 with 2 doses of mRNA-1273 (SpikeVax; Moderna) compared to two doses of BNT162b2 (Comirnaty; Pfizer/BioNTech). The main objective of this retrospective cohort study was to compare real-world effectiveness of third doses of mRNA-1273 versus BNT162b2 at multiple time points on occurrence of COVID-19 hospitalization and medically-attended COVID-19 among IC adults in the US. The HealthVerity (HV) medical and pharmacy claims database, which contains data from >330 million patients, was the data source. Both subgroup and sensitivity analyses were conducted in addition to the core comparisons noted. In propensity score-adjusted analyses, receiving mRNA-1273 vs BNT162b2 as third dose was associated with 32% (relative risk [RR] 0.68; 95% confidence interval [CI] 0.51-0.89), 29% (0.71; 0.57-0.86), and 23% (0.77; 0.62-0.93) lower risk of COVID-19 hospitalization after 90, 180, and 270 days, respectively. Corresponding reductions in medically-attended COVID-19 were 8% (0.92; 0.86-0.98), 6% (0.94; 0.90-0.98), and 2% (0.98; 0.94-1.02), respectively. Our findings suggest a third dose of mRNA-1273 is more effective than a third dose of BNT162b2 in preventing COVID-19 hospitalization and breakthrough medically-attended COVID-19 among IC adults in the US.

2019-20 coronavirus outbreak

Real world evidence

10.1101/2024.01.30.24302015

Cite

Citations (1)

Trends in gonococcal infection: no room for complacency.

Sexually Transmitted Infections (1990)

Patrick French Jenny Davis David Goldmeier Ekkehard Beck

Gonococcal infection

Neisseria gonorrhoeae

10.1136/sti.66.4.302-a

Cite

Citations (10)